Salesforce vs. UiPath: Which Technology Stock Is a Better Buy in 2026?

Salesforce generated FY2026 revenue of nearly $41.5B (+9.6% YoY), net income of about $7.5B, and free cash flow of roughly $14.4B, while UiPath reached profitability with $1.6B of revenue (+12.7%), $282.3M of net income, and $352.2M of free cash flow. Salesforce trades at a lower 14.2x forward P/E versus UiPath's 17.0x, though UiPath has a slightly lower 4.4x P/S ratio versus 4.7x. The article favors Salesforce for its scale, profitability, Agentforce AI adoption, and AI/data-cloud growth, while noting UiPath's turnaround and balance-sheet strength but more uncertain investor confidence.

Analysis

The relevant debate is not CRM versus PATH headline profitability; it is whether agentic AI expands incumbent platform spend or commoditizes point automation. CRM controls customer data, identity, workflow distribution, and a large installed base, allowing AI functionality to be packaged into broader enterprise agreements. That should support net-revenue retention and reduce sales friction over the next 6-18 months if paid AI adoption converts to recurring subscription uplift rather than services-heavy pilots.

PATH is more exposed to the adverse version of this transition: LLM-native workflow tools from MSFT, ServiceNow (NOW), and CRM can absorb lower-complexity RPA use cases into existing platform budgets. Its apparent cash-generation improvement warrants skepticism because equity compensation remains the primary economic cost; sustained margin expansion must show up in dilution-adjusted FCF and accelerating annual recurring revenue, not merely GAAP profitability. Conversely, PATH can re-rate sharply over 1-3 months if AI-orchestration deployments demonstrably increase expansion rates among its largest accounts, as its debt-free balance sheet limits downside from a slower enterprise spend cycle.

Consensus is likely too focused on reported valuation multiples. CRM's multiple can expand if AI monetization raises its durable growth rate without reaccelerating operating expense, while PATH's lower sales multiple offers little protection if revenue growth remains near low teens and dilution persists. The immediate article impact is low; the investable catalysts are upcoming bookings, remaining-performance-obligation, AI attach-rate, and operating-margin disclosures rather than the comparison itself.

For CRM, falsification is a material deceleration in cRPO/RPO, AI demand failing to translate into subscription growth, or renewed margin pressure from go-to-market spending. For PATH, require evidence that large-customer concentration is becoming an expansion engine rather than a renewal risk; a guidance cut, falling dollar-based net retention, or share-count growth that exceeds FCF growth invalidates the turnaround thesis.

Key Decisions for Investors

• Maintain/establish a 6-12 month long CRM position versus a short PATH hedge (equal dollar, rebalance around earnings). The trade expresses platform-distribution advantage in agentic AI; target 15-25% relative outperformance, with exit if PATH ARR growth accelerates above CRM's by more than 5 points for two consecutive quarters while dilution normalizes.
• Add CRM only on post-earnings confirmation that cRPO/RPO growth and operating margin both improve; avoid chasing generic AI-deal announcements. Risk is a costly AI sales cycle that lifts bookings but delays revenue conversion; trim if forward revenue growth decelerates despite higher AI commentary.
• Keep PATH as a watch-list long rather than a core allocation until management discloses durable improvement in net retention, large-account expansion, and dilution-adjusted FCF. A 1-3 month tactical long becomes actionable only after a guidance raise tied to recurring automation/AI consumption rather than restructuring or one-time profitability effects.
• Monitor MSFT and NOW as competitive read-throughs: stronger Copilot or workflow-AI attach rates without corresponding PATH enterprise expansion would reinforce the short leg. A broad enterprise-software risk-off move is not a clean relative catalyst; use the pair rather than outright beta exposure.